Emerging Treatments in HIV

Feature Article

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.

Latest News

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.

FDA Grants Priority Review to Single Tablet HIV Regimen

FDA Grants Priority Review to Single Tablet HIV Regimen

The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

Long-Acting Injectable Antiretrovirals for HIV Effective and Safe

The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

Efficacy, Safety of Fixed-Dose HIV Regimen With Bictegravir Evaluated

Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.

Atazanavir/Ritonavir Plus Lamivudine is as Safe, Effective as Triple Therapy

Atazanavir/Ritonavir Plus Lamivudine is as Safe, Effective as Triple Therapy

Dual combination ART with atazanavir/ritonavir plus lamivudine demonstrated similar efficacy and safety as atazanavir/ritonavir plus 2 NRTIs at 48 weeks in the ATLAS-M trial.

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

Switching to TAF-based regimen was non-inferior to continuing TDF-based regimen in maintaining viral suppression.

Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

Sign Up for Free e-newsletters